VivoSeq
Other

Nephrectomy

0

Pipeline Programs

1

Active Trials

1

Companies Involved

Nephrectomy is an early-stage landscape with 0 programs across 1 company. The most active players are OMRIX Biopharmaceuticals.

Pipeline Metrics

Competitive Density

6/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

82/100

Attrition Rate

17/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Programs by Phase

No pipeline programs currently tracked for this disease.

Trial Status

12

clinical trials

Completed9 · 75%
Recruiting1 · 8%
Terminated1 · 8%
Withdrawn1 · 8%

Trial Activity

12 trials

NSAID Use After Robotic Partial Nephrectomy
Recruiting·UUniversity of Miami·Phase 2·NCT05842044·110 enrolled
PaNeX: Partial Nephrectomy Under Xenon
Completed·RRWTH Aachen University·Phase 3·NCT01839084·46 enrolled
QLB After Nephrectomy
Completed·MMedical University of Lublin·N/A·NCT03529201·105 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)